Overview

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This trial is a monocentric, randomised, double-blind, active comparator, controlled, 3-period cross-over trial.
Phase:
Phase 1
Details
Lead Sponsor:
Adocia
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc
Islet Amyloid Polypeptide
Pramlintide